Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase 3 2

Status

Completed 31Terminated 13Unknown 6Active not recruiting 5Withdrawn 4Recruiting 4Not yet recruiting 1

Sponsor Class

OTHER 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 5Prostate Cancer, Hereditary, 7 1

Interventions

pembrolizumab 198Nivolumab 146Carboplatin 133Specimen Handling 130Magnetic Resonance Spectroscopy 116Cyclophosphamide 112Paclitaxel 106Biopsy 97Cisplatin 94Radiotherapy 89durvalumab 83Dexamethasone 80atezolizumab 73Ipilimumab 66Gemcitabine 60Doxorubicin 60Rituximab 59Lenalidomide 56Docetaxel 55olaparib 51Etoposide 51Bevacizumab 51Fluorouracil 49Capecitabine 49Radiation 47Oxaliplatin 47Radiosurgery 43Prednisone 43venetoclax 41Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × cabazitaxel × Clear all
NCT04709276 2026-04-06

CHAMP

Duke University

Phase 2 Active not recruiting
41 enrolled
Genitourinary

Prostatic Neoplasms

NCT03419234 2026-04-01

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
223 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

NCT02703623 2026-03-06

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
196 enrolled
Genitourinary

Prostatic Neoplasms

NCT03263650 2026-02-17

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
96 enrolled
Genitourinary

Prostate Cancer, Hereditary, 7, Prostatic Neoplasms

NCT04592237 2025-12-23

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
120 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡